If patients with measurable or evaluable disease have a response of stable disease or better by RECIST criteria at the day 28 evaluation after dose 2 or subsequent evaluations they are eligible to receive up to 6 additional doses of CTLs at monthly intervals. Each subsequent dose will be at the enrollment dose level (i.e. no subsequent dose escalation). Patients will not be able to receive additional doses until the initial safety profile is completed at day 28 following the second infusion.